Pulmonary Edema Model
Discover how Melior’s unique phenotypic screening platforms can uncover the untapped value of your candidate therapeutic
Pulmonary edema is caused by leakiness or extravasation of pulmonary blood vessels that can be associated with a number of pulmonary disease conditions including COVID-19. Fluid laden pulmonary alveoli have poor oxygen exchange rates and are associated with reduced respiratory function. Patients experience lower oxygen saturation levels (SpO2) leading to Acute Respiratory Distress Syndrome (ARDS) causing multiple organ failure and death. In this regard, pulmonary edema is a critical component among a sequence of events in respiratory disease such as COVID-19 that lead to death. Therapeutic agents that can prevent or mitigate pulmonary edema may be life-saving.
Melior uses a pulmonary edema model that recapitulates important aspects of the human condition. Specifically, systemic inflammation is induced with a bolus administration of lipopolysaccharide (LPS) systemically (IP) or intranasally (IN) . The ensuing pulmonary edema can be monitored by measuring lung wet weight / dry weight ratio or by systemic administration of Evan’s Blue dye followed by dye extraction from lung tissue.
The study outlined below illustrates the pulmonary edema model in C57BL/6 mice created by an LPS-induced cytokines storm. Dexamethasone, which attenuates this cytokine storm, significantly reduces the pulmonary edema.
The mouse pulmonary edema model is typically run as an acute model (one/two day day study, 6-48 hrs after LPS administration) with a single administration of test article. In addition to monitoring measures of edema it is also common to incorporate measures of cytokines such as IL-6, TNF-α, and MCP-1.